Oncology Pharma Inc.
20.7.2021 13:32:38 CEST | ACCESS Newswire | Press release
SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support studies, to obtaining the data utilizing mouse or rat clinical trials ("Mouse clinical trials" or "MCT") all steps are being established. The Company has decided to pursue moving forward with MCT as it most closely represents the setting of a human clinical trial.
Human preclinical methods are different as they use a small number of models with a large number of tests per subject. Mouse clinical trials tend to upend the traditional preclinical paradigm and better resemble and match the actual clinical setting. The Company believes this is an effective and cost-efficient way of moving forward. Utilizing MCTs will develop data that can be leveraged for biomarker discovery, which is ever more crucial for clinical trial success.
In addition, the Company continues to develop its business model to support the currently licensed IP and providing them with the necessary tools each individual licensor needs to support their individual business so they can contribute to the business plan of Oncology Pharma, Inc.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Website: www.oncology-pharma.com
Email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/656221/Oncology-Pharma-Inc-To-Move-to-Conducting-Trials-on-Licensed-IP
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
LiberNovo Omni SE, Omni Pro and Maxis Enter Final Week of Early Bird Launch Pricing24.7.2026 09:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / July 24, 2026 / Seven days is what remains of LiberNovo's 2026 launch pricing. Across the EU and UK, Omni SE, Omni Pro, and the Maxis series hold their early bird prices until July 31, and the window closes there. The whole lineup is built around dynamic ergonomics: the support system links the neck support, backrest, armrests, and seat, so everything moves together as you shift, lean, and recline. The chair follows the movement; you get on with the work. A quick way to choose Omni SE: the simplest build in the lineup. No motor and no battery; you set the lumbar depth by hand and the automatic support does the rest. Solid dynamic ergonomics at the friendlier price. Better Comfort, Simplified. Omni Pro: the premium chair in the lineup. Motorized lumbar adjustment and the OmniStretch guided back stretch at the press of a button, plus Active Airflow ventilation built into the seat for long days and warm rooms, an aluminum base, and Danish Gabriel fabric.
2026 Fields Medals Awarded to Four of World's Top Mathematicians23.7.2026 16:45:00 CEST | Press release
The award, nicknamed the Nobel Prize of mathematics, recognizes outstanding achievement - and the promise of future achievement - by mathematicians under 40. PHILADELPHIA, PA / ACCESS Newswire / July 23, 2026 / During today's opening ceremony at the International Congress of Mathematicians (ICM) in Philadelphia, the International Mathematical Union (IMU) announced the recipients of the 2026 Fields Medals. This year's prizes went to four of the world's top mathematicians: Chinese mathematician Yu Deng of the University of Chicago; American mathematician John Pardon of Stony Brook University in New York; Canadian mathematician Jacob Tsimerman of the University of Toronto; and Chinese mathematician Hong Wang of New York University and France's Institut des Hautes Études Scientifiques (IHES). The Fields Medal is often described as the Nobel Prize of mathematics due to its prestige. Awarded every four years to two to four mathematicians under the age of 40, the medal recognizes outstanding
Karbon-X Secures Technical Advisory Engagement for Nature-Based Carbon Project in Libya22.7.2026 15:00:00 CEST | Press release
Initial engagement expands the Company's international project development portfolio through technical advisory services supporting the design and optimization of a proposed nature-based carbon project. CALGARY, AB / ACCESS Newswire / July 22, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets and climate infrastructure, today announced that it has been engaged by Stream Pro Ltd, a subsidiary of Oilinvest to provide technical advisory services supporting the design and value optimization of a proposed nature-based carbon project in Libya. The engagement represents another step in Karbon-X's international project development strategy and further demonstrates the Company's expertise in the design and development of high-integrity carbon projects across emerging markets. Under the initial scope of work, Karbon-X will provide end-to-end technical support for the project's carbon design,
U.S. Polo Assn. Sponsors the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup as Official Apparel Partner22.7.2026 13:00:00 CEST | Press release
Gaston Polo Team Claims Gold Cup Title Over Dubai Polo Team at Cowdray Park Polo Club WEST PALM BEACH, FL AND WINDSOR, UK / ACCESS Newswire / July 22, 2026 / U.S. Polo Assn.® in partnership with Brand Machine Group (BMG), its partner in the United Kingdom, proudly continued its long-standing support of the British high-goal season as the Official Apparel Partner of the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup, held June 23 through July 19 at Cowdray Park Polo Club, known widely as "The Home of British Polo." 1) 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup Winners, Gaston Polo Team, accepting trophy on stage at Cowdray Park Polo Club 2) Gaston Polo Team attacking the ball against Dubai Polo Team in the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup Final 3) The British Ladies Open Championship Finalists, Yaguara and Salty Polo, on stage at Cowdray Park Polo Club 4) U.S. Polo Assn.'s Experiential Merchandise
House of Hope in Bamako Continues to Provide Vital Support for Vulnerable Women in Mali in 202622.7.2026 11:00:00 CEST | Press release
BUDAPEST, HUNGARY / ACCESS Newswire / July 22, 2026 / The Gedeon Richter House of Hope centre in Bamako, Mali, continued to provide comprehensive support for vulnerable women and girls during the first half of 2026, delivering healthcare, protection, counselling, education and vocational training through its integrated programme. In the first six months of is year, nearly 50 women have been provided assistance in the center. Established through the cooperation of Gedeon Richter, the Hungary-based Close to Africa Foundation, and local partner Sini Sanuman Foundation, the House of Hope opened at the beginning of 2025 to offer shelter, gynaecological care, psychosocial and legal support, as well as educational and skills-development opportunities to women affected by violence and harmful traditional practices. Since opening its doors, the centre has supported well over a hundred women, while community outreach and awareness-raising activities have reached many more across Bamako and surro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom